TY  - JOUR
T1  - TIme to rethink psa screening
AU  - Singh PB, Ahmed HU, Simmons L, Freeman A, Emberton M
Y1  - 2011/03/28
N1  - 10.1001/archinternmed.2011.81
JO  - Archives of Internal Medicine
SP  - 595
EP  - 595
VL  - 171
IS  - 6
N2  - 
We read with interest the article by Shao et al1 looking at the risk profile of newly diagnosed prostate cancer and treatment patterns in the US population. The finding that men with screen-detected cancers and a PSA value less than 4 ng/mL were more likely to receive radical therapies despite having lower-risk disease is alarming. It will, however, come as no surprise to the uro-oncology community, which has debated the merits of therapy that causes significant genitourinary and bowel adverse effects2 but requires 12 men to be treated to extend the life of 1 man over a period of 15 years.3

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2011.81
UR  - http://dx.doi.org/10.1001/archinternmed.2011.81
ER  -